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Patients with chronic heart failure (CHF) have a resting restrictive ventilatory defect. Any
type of exercise requires patients with CHF to markedly increase their minute ventilation.
Patients with chronic obstructive pulmonary disease (COPD) have airflow obstruction that
leads to dynamic lung hyperinflation and reduced ventilatory response to exercise. Because
exercise is associated with abnormally high minute ventilation in patients with CHF and with
a limited minute ventilation increase in patients with COPD, functional capacity is severely
impaired in patients with coexistent CHF and COPD. Optimal treatment of both conditions
is a prerequisite to maximally improve functional capacity in patients with CHF and COPD.
Unfortunately, beta-adrenergic blockade, the current cornerstone of CHF therapy, is
frequently omitted in patients with CHF and COPD for fear of inducing bronchoconstric-
tion. Furthermore, when prescribed, beta-adrenergic blockade is often attempted with a
moderate dose of metoprolol tartrate, a beta-1-blocker that results in lesser clinical benefits
than combined non-selective beta-blockade with carvedilol at the maximally recommended
dose. Recent experience indicates that combined non-selective beta- and alpha-blockade with
carvedilol is well tolerated in patients with COPD who do not have reversible airway
obstruction. Alpha-adrenergic blockade may promote mild bronchodilation that offsets
non-selective beta blockade-induced bronchoconstriction in patients with obstructive airway
disease. (J Am Coll Cardiol 2004;44:497–502) © 2004 by the American College of
Cardiology Foundationw
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bhe coexistence of chronic heart failure (CHF) and chronic
bstructive pulmonary disease (COPD) exposes patients to
ouble jeopardy. From a diagnostic standpoint CHF can
emain undiagnosed in patients with COPD. The symptoms
f CHF and COPD are similar, and the increase in lung
olumes associated with COPD hampers palpation of a large
eart and/or auscultation of a third heart sound. Furthermore,
he acoustic window is frequently poor in patients with
OPD, thereby impeding evaluation of cardiac function by
wo-dimensional Doppler echocardiography. From a thera-
eutic standpoint, the coexistence of COPD and CHF can be
esponsible for suboptimal therapy because fear of inducing
evere bronchoconstriction leads physicians to withhold beta-
drenergic blockade in these patients. Beta-adrenergic block-
de has become the cornerstone of CHF therapy because, aside
rom cardiac transplantation, it is the only intervention that
oth reverses cardiac dilation and enhances myocardial con-
ractility (1–4).
Beta-adrenergic blockade-induced bronchoconstriction
ccurs more often in patients with asthma than in patients
From the *Department of Medicine, Albert Einstein College of Medicine, Bronx,
ew York; †Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia
niversity College of Physicians and Surgeons, New York, New York; and ‡Division
f Cardiology, Albert Einstein College of Medicine, Bronx, New York.
Manuscript received October 24, 2003; revised manuscript received March 22,w004, accepted March 30, 2004.ith COPD (5–9). Bronchoconstriction also occurs more
requently with non-selective beta-blocking agents than
ith selective beta-1 agents (10). Selective beta-1–blocking
gents do not appear to affect short-term airway function or
o increase the incidence of exacerbations in patients with
OPD (11), although they significantly reduce mortality
fter an acute myocardial infarction in these patients
12,13).
The prevalence of COPD in patients with known CHF
anges from 23% to 33% (14,15). The number of patients
ith COPD and CHF will rise with prolonged life expect-
ncy, as both conditions become increasingly more prevalent
ith age. As the age-adjusted death rate for COPD
ontinues to rise and the mortality of patients with CHF
emains high, the importance of treating both conditions
ptimally cannot be emphasized enough (16,17).
In this brief review we will first summarize how pulmo-
ary abnormalities in COPD and CHF have a compound-
ng effect on limiting the ventilatory response to exercise.
e will then review the experience with beta-1 selective
drenergic blockade in patients with COPD. Last, in view
f a recent increased interest in carvedilol, we will review the
afety profile of combined non-selective beta- and alpha-
drenergic blockade in patients with COPD and the risk-
enefit ratio of this pharmacologic intervention in patients
ith COPD and CHF (1).
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atients with CHF have a restrictive ventilatory defect and
educed lung diffusing capacity for carbon monoxide
DLCO) (18). Pulmonary congestion, interstitial fibrosis,
ardiac enlargement, and respiratory muscle weakness are
esponsible for the restrictive ventilatory defect (19–22). Of
ote, the restrictive ventilatory defect regresses after cardiac
ransplantation, whereas DLCO does not improve (23).
Patients with COPD have progressive airflow obstruction
hat may be partially reversible (24). Destruction of lung
issue leading to ventilation-perfusion mismatch and in-
reased physiologic dead space results in increased minute
entilation in order to maintain blood gas homeostasis (25).
esting minute ventilation in patients with moderately
evere COPD averages 10 l/min, whereas it is 5 l/min in
ealthy adults.
Restrictive ventilatory defect is the predominant pulmo-
ary abnormality in patients with CHF (26). Their forced
ital capacity (FVC) and forced expiratory volume in 1 s
FEV1) are normal or proportionally reduced. In contrast,
he majority of patients with COPD have a greater reduc-
ion in FEV1 than in FVC, consistent with an obstructive
entilatory defect (24). However, FVC and FEV1 may be
qually reduced in patients with severe COPD due to gas
rapping. A near-normal FEV1-to-FVC ratio suggests a
estrictive ventilatory defect in these patients. Because a
estrictive ventilatory pattern does not exclude the presence
f airway obstruction in patients with CHF and COPD,
easurement of lung volumes may be required to ascertain
he predominant ventilatory defect. Total lung capacity and
esidual volume are increased with predominant obstruction
nd are decreased with predominant restriction. Reduced
VC is an independent predictor of cardiovascular morbid-
ty and mortality in healthy subjects (27). It also predicts the
eart failure risk in patients with coronary artery disease or
eft ventricular hypertrophy (28).
The ventilatory response to exercise is abnormal in
atients with CHF (29–32). Minute ventilation is 69%
reater than normal in patients with CHF whose peak
xygen uptake (VO2) is 12 ml/min/kg (26). The mecha-
isms underlying the abnormally high ventilatory response
o exercise in CHF are not well understood. The magnitude
Abbreviations and Acronyms
CHF  chronic heart failure
CI  confidence interval
COPD  chronic obstructive pulmonary disease
DLCO  lung diffusing capacity for carbon monoxide
FEV1  forced expiratory volume in 1 s
FVC  forced vital capacity
PaCO2  partial arterial pressure of carbon dioxide
ROS  reactive oxygen species
VD/VT  ratio of physiologic dead space to tidal volume
WMD  weighted mean differencef the ventilatory response is inversely related to the partial crterial pressure of carbon dioxide (PaCO2) and directly
elated to peak carbon dioxide production (VCO2) and the
ead-space-to-tidal-volume ratio (VD/VT) (26). Increased
CO2 and VD/VT and reduced PaCO2 without arterial
ypoxemia or increased alveolar-arterial oxygen tension
radient are indirect evidences of high but not low ventila-
ion/perfusion ratio mismatch during exercise in CHF (26).
neven elevation in pulmonary venous pressure is a likely
ontributor to ventilation-perfusion mismatching. Reduc-
ion in perfusion pressure gradient due to elevated pulmo-
ary venous pressure leads to reduced perfusion (26).
During exercise, patients with COPD attempt to further
ncrease minute ventilation. As they cannot increase tidal
olume by reducing end-expiratory lung volume due to
ynamic hyperinflation, patients with COPD rely on in-
reasing respiratory rate to augment minute ventilation
33,34). Patients with COPD also tend to increase inspira-
ory flow rate in order to allow more time for exhalation.
In order to attain the minute ventilation required to
aintain blood gas homeostasis during exercise, patients
ith CHF need to generate a greater ventilatory response
han normal subjects. Airway obstruction prevents patients
ith coexistent CHF and COPD from increasing ventila-
ory response during exercise, resulting in severely impaired
unctional capacity (Fig. 1). The relative contribution of
irway obstruction and lung restriction to pulmonary func-
ion and gas exchange has not been specifically addressed at
est and during exercise in patients with CHF and COPD.
evertheless, optimal management of both conditions is
ssential in order to maximally enhance functional capacity
hen CHF and COPD coexist.
XPERIENCE WITH
ETA-ADRENERGIC-BLOCKADE IN COPD
ost likely for safety considerations, patients with COPD
ere excluded from most randomized placebo-controlled
rials of beta-adrenergic blocking agents in CHF (1–4).
ased on case reports of bronchoconstriction induced by
on-selective beta-adrenergic blocking agents, CHF guide-
ines routinely mention COPD as a contraindication to
heir use in CHF (5–9). Beta-2-receptors predominate on
ronchial smooth muscle, whereas beta-1-receptors account
or 10% and 30% of adrenoreceptors in submucosal glands
nd on alveolar walls, respectively (35). Selective beta-1–
locking agents have an affinity for beta-1-receptors that is
0-fold greater than for beta-2-receptors. Selective beta-1–
locking agents are thus less likely to induce bronchocon-
triction than are non-selective agents (10). However, se-
ective beta-1–blocking agents appear to lose receptor
electivity at the high end of dose ranging (36,37).
ELECTIVE BETA-1-ADRENERGIC BLOCKADE
nlike non-selective agents such as propranolol and oxpre-
olol that significantly reduce FEV1 and inhibit the bron-
hodilator response to the inhaled beta-agonist salbutamol,
s
p
a
M
n
d
a
(
r
s
(
w
r
b
b
(
a
c
b
i
d
[
w
w
c
(
i
s
c
w
[

a
p
h
3
a
C
N
A
F
b
c
l
C
p
w
f
C
a
d
r
T
w
o
d
c
A
d
o
a
e
c
s
t
a
l
a
s
F
m
w
r
d
d
e
b
f
p
v
P
t
D
(
499JACC Vol. 44, No. 3, 2004 Sirak et al.
August 4, 2004:497–502 Non-Selective Beta-Blockade in COPD and CHFelective beta-1–blocking agents such as atenolol and celi-
rolol do not significantly affect respiratory function or
ntagonize salbutamol effects in patients with COPD (38).
etoprolol, another selective beta-1–blocking agent, does
ot significantly affect FEV1 or FVC at a dose of 200 mg
aily when compared with placebo in patients with moder-
tely severe COPD and significant reversible component
39). A single 80-mg dose of propranolol significantly
educes FEV1 and peak expiratory flow rate in patients with
evere COPD, whereas 100 mg of metroprolol does not
40). Whether metoprolol tartarate or metoprolol succinate
as used is not specified (39,40). A meta-analysis of 19
andomized placebo-controlled trials of selective beta-1–
locking agents confirms their lack of effects on FEV1 and
ronchodilator response to beta-2-adrenergic stimulation
11). Selective beta-1–blocking agents included in a meta-
igure 1. The top panel (A) depicts the resting cardiopulmonary abnor-
alities that are responsible for a restrictive ventilatory defect in patients
ith chronic heart failure (CHF). When patients with CHF exercise,
estrictive ventilatory defect, increased dead space (VD/VT) and carbon
ioxide production (VCO2), and decreased partial arterial pressure of carbon
ioxide (PaCO2) lead to ventilation/perfusion mismatch and worsened gas
xchange and lung-diffusing capacity for carbon monoxide (DLCO). The
ottom panel (B) depicts the pulmonary abnormalities that are responsible
or obstructive ventilatory defect in patients with chronic obstructive
ulmonary disease (COPD). When these patients exercise, obstructive
entilatory defect, dynamic hyperinflation, increased respiratory rate and
aCO2 as well as decreased partial arterial pressure of oxygen (PaO2) lead
o increased ventilation/perfusion mismatch, decreased gas exchange, and
LCO that compound the effects of CHF on these same parameters
CHFCOPD). 1  increased; 2  decreased; 8  unchanged.nalysis were atenolol, metoprolol, bisoprolol, practolol, Celiprolol, and acebutol. Single doses of selective beta-1–
locking agents were not associated with significant change
n FEV1 compared to placebo, with a weighted mean
ifference (WMD) of 2.05% (95% confidence interval
CI]: 6.05 to 1.96) in 11 studies involving 141 patients
ith COPD. Long-term therapy, ranging from 2 days to 12
eeks, with selective beta-1–blocking agents was not asso-
iated with significant change in FEV1 compared to placebo
WMD 2.55% [95% CI: 5.94 to 0.84]) in eight studies
nvolving 126 patients with COPD. Bronchodilator re-
ponse to beta-2-adrenergic stimulation was not signifi-
antly different after single-dose or long-term treatment
ith selective beta-1–blocking agents (WMD 1.21%
95% CI: 10.97 to 8.56] and WMD 2.0% [95% CI:
13.77 to 9.77], respectively). Selective beta-1–blocking
gents do not increase respiratory symptoms in stable
atients with severe airflow obstruction, or in those who
ave a significant reversible obstructive component (11,
8–40). However, the effects of selective beta-1–blocking
gents on pulmonary function and symptoms during
OPD exacerbation are not available.
ON-SELECTIVE BETA- AND
LPHA-ADRENERGIC BLOCKADE
ewer studies have dealt with agents that exert non-selective
eta- and alpha-adrenergic blockade, such as labetalol and
arvedilol, in patients with COPD. A maximal dose of
abetalol does not affect FEV1 in these patients (41).
arvedilol has no effect on lung volumes and DLCO in
atients with CHF and no obstructive airway disease,
hereas it significantly increases left ventricular systolic
unction at rest (42). Among 89 patients with coexistent
OPD or asthma and CHF, 76 tolerated carvedilol well for
t least three months (43). Why the remaining 13 patients
id not tolerate carvedilol, or how many of them had
eversible airway obstruction, was not commented on (43).
hirty-one patients with coexistent CHF and COPD
ithout reversible airflow obstruction receiving a mean dose
f 29  19 mg daily of carvedilol were followed for a mean
uration of 2.4 years (44). Only one patient did not tolerate
arvedilol because of exacerbation of pulmonary disease.
mong the 12 patients with coexistent CHF and asthma, 3
id not tolerate carvedilol because of wheezing. At the time
f carvedilol withdrawal patients were receiving 6.25, 12.5,
nd 50 mg of carvedilol, respectively (44). To our knowl-
dge no data are currently available regarding the use of
arvedilol in COPD patients with reversible airflow ob-
truction.
The beneficial effect of beta-adrenergic blockade in pa-
ients with coexistent CHF and COPD is difficult to
scertain because such patients have been excluded from all
arge efficacy trials to date. However, long-term beta-
drenergic blockade after myocardial infarction improves
urvival to the same extent in patients with and without
OPD (12,13). Thus, the American College of Cardiology
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Non-Selective Beta-Blockade in COPD and CHF August 4, 2004:497–502nd the American Heart Association updated their guide-
ines for the treatment of acute myocardial infarction to
mphasize that the survival benefit from beta-blockade
argely outweighs the risk of adverse events in patients with
OPD (45). Cardiac size and function improved similarly
n patients with coexistent CHF and COPD and in patients
ith CHF alone after receiving non-selective beta- and
lpha-adrenergic blockade for 24 months (44,46,47).
Selective beta-1-adrenergic blockade enhances maximal
xercise capacity in patients with CHF, whereas non-
elective adrenergic-blockade does not (48). More complete
eta-blockade with non-selective agents may explain the
ontrasting effect of selective and non-selective beta-
lockade on maximal exercise capacity. Quality of life and
ubmaximal response to exercise, which more closely reflect
ctivities of daily living, tend to improve, or at least not
orsen, with non-selective agents despite the more com-
lete beta-blockade (49–53).
ECHANISMS OF BETA-ADRENERGIC
LOCKADE-INDUCED BRONCHOCONSTRICTION
he mechanisms that mediate beta-adrenergic blockade-
nduced bronchoconstriction in patients with COPD are
ot well understood. Beta-adrenergic stimulation inhibits
elease of acetylcholine, a potent bronchoconstrictor, from
holinergic nerves in human airways (54). In patients with
sthma, non-selective beta-adrenergic blockade may cause
ronchoconstriction by antagonism of inhibitory presynap-
ic beta-2-adrenoreceptors on cholinergic nerves (55). Beta-
drenergic blockade-induced bronchoconstriction does not
ccur in healthy subjects. Their airways are less sensitive to
he constrictor effect of acetylcholine than those of asth-
atic patients (56). Patients with COPD, unlike those with
sthma, experience equal or better bronchodilator responses
o anticholinergic agents than to beta-adrenergic agonists
57,58). Beta-2-adrenoreceptors and cholinergic M2 recep-
ors have opposite effects on adenylyl cyclase activity. Thus
timulation of these receptors increases or decreases the
yclic adenosine monophosphate level, respectively. A rise
n cyclic adenosine monophosphate level relaxes smooth
irway muscle (59). Stimulation of cholinergic M2 receptors
educes adenylyl cyclase activity, thereby counteracting beta-
-agonist–induced airway smooth muscle relaxation
60,61). Accordingly, beta-adrenergic blockade may result
n unopposed acetylcholine-mediated bronchoconstriction.
onsiderable heterogeneity of cholinergic M2 receptors in
atients with COPD may explain the variability in the
irway response to beta-adrenergic blockade (62).
Alternatively, the bronchoconstrictor effect of beta-
lockers may not be directly related to beta-adrenoreceptor
lockade (63,64). Alpha-1-adrenergic–blocking agents such
s phentolamine and indoramine produce mild bronchodi-
ation in patients with obstructive airway disease and abolish
ropranolol-induced bronchoconstriction (65–67). Prazo-
in, an alpha-1–blocking agent, does not affect the respira-ory function of healthy subjects and patients with asthma or
OPD. To the contrary, prazosin may exert an appreciable
ronchodilator effect (68). Thus, partial or complete beta-
-adrenoreceptor blockade with unopposed activation of
lpha-receptors may be responsible for bronchoconstriction
nduced by non-selective beta-blockade. Alpha-1–blocking
ctivity of carvedilol and labetalol may be sufficient to offset
eta-adrenergic blockade-induced bronchoconstriction in
atients with COPD, but not in patients with asthma
41,69).
UMMARY
bstructive ventilatory defect in patients with COPD
ggravates the impaired ventilatory response to exercise in
atients with CHF. Thus, at equal severity of CHF,
atients with coexistent COPD and CHF have a lower
unctional capacity than patients with CHF alone. Accord-
ngly, optimal therapy of CHF is particularly important in
atients with coexistent COPD and CHF in order to
aximally improve functional capacity. Selective beta-1-
drenergic blockade is routinely preferred to non-selective
lockade in patients with coexistent COPD and CHF to
inimize the risk of inducing bronchoconstriction. How-
ver, recent limited evidence indicates that combined non-
elective beta- and alpha-adrenergic blockade is well toler-
ted by patients with COPD who do not have reversible
irway obstruction. Selective beta-1-blockade or non-
elective beta- combined with alpha-adrenergic blockade
hould not be withheld in patients with CHF and COPD
ithout reversible airway obstruction. Past experience with
elective beta-1-blockade and recent experience with com-
ined beta- and alpha-adrenergic blockade does not support
he fear of inducing bronchoconstriction in these patients.
n patients with CHF and COPD with reversible airway
bstruction, selective beta-1-blockade remains the preferred
pproach in the absence of safety data on agents combining
on-selective beta- with alpha-adrenergic blockade. Selec-
ive beta-1-blockade and non-selective beta- combined with
lpha-adrenergic blockade should be avoided during COPD
xacerbation until safety data are available.
eprint requests and correspondence: Dr. Thierry H. Le Jemtel,
epartment of Medicine, Division of Cardiology, Room G46, Albert
instein College of Medicine, 1300 Morris Park Avenue, Bronx,
ew York 10461. E-mail: lejemtel@aecom.yu.edu.
EFERENCES
1. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of
carvedilol and metoprolol on clinical outcomes in patients with chronic
heart failure in the Carvedilol Or Metoprolol European Trial (COM-
ET): randomized controlled trial. Lancet 2003;362:7–13.
2. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival
in severe chronic heart failure. N Engl J Med 2001;344:1651–8.
3. CIBIS-II Investigators and Committees. The Cardiac Insufficiency
Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:
9–13.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
501JACC Vol. 44, No. 3, 2004 Sirak et al.
August 4, 2004:497–502 Non-Selective Beta-Blockade in COPD and CHF4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic
heart failure: Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7.
5. The Joint National Committee. The sixth report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure. Arch Intern Med 1997;157:2413–46.
6. Craig T, Richerson HB, Moeckli J. Problem drugs for the patient with
asthma. Compr Ther 1996;22:339–44.
7. O’Malley K, Cox JP, O’Brien E. Choice of drug treatment for elderly
hypertensive patients. Am J Med 1991;90 Suppl 3A:27S–33S.
8. Tattersfield AE. Beta adrenoreceptor antagonists and respiratory
disease. J Cardiovasc Pharmacol 1986;8 Suppl 4:S35–9.
9. Tattersfield AE. Respiratory function in the elderly and the effects of
beta blockade. Cardiovasc Drugs Ther 1990;4:1229–32.
0. Wellstein A, Palm D, Belz G, Butzer R, Polsak R, Pett B. Reduction
of exercise tachycardia in man after propranolol, atenolol and bisopro-
lol in comparison to beta-adrenoceptor occupancy. Eur Heart J 1987;8
Suppl M:3–8.
1. Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates C. Cardioselec-
tive beta-blockers for chronic obstructive pulmonary disease. Cochrane
Database Syst Rev 2002;2:CD003566.
2. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on
mortality among high-risk and low-risk patients after myocardial
infarction. N Engl J Med 1998;339:489–97.
3. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM.
Effectiveness of beta-blocker therapy after acute myocardial infarction
in elderly patients with chronic obstructive pulmonary disease or
asthma. J Am Coll Cardiol 2001;37:1950–6.
4. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL,
Krumholz HM. Spectrum of heart failure in older patients: results
from the National Heart Failure project. Am Heart J 2002;143:412–7.
5. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart
failure in the community: a study of all incident cases in Olmsted
County, Minnesota, in 1991. Circulation 1998;98:2282–9.
6. Higgins MW, Thorn T. Incidence, prevalence, and mortality: intra-
and inter-county differences. Hensley MJ, Saunders NA, eds. Clinical
Epidemiology of Chronic Obstructive Pulmonary Disease. New York,
NY: Marcel Dekker, 1990:23–43.
7. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin
2001;19:547–55.
8. Dimopoulou I, Dagano M, Tsintzas OK, Tzelepis GE. Effects of
severity of long-standing congestive heart failure on pulmonary func-
tion. Respir Med 1998;92:1321–5.
9. Hosenpud JD, Stibolt TA, Atwal K, Shelly D. Abnormal pulmonary
function specifically related to congestive heart failure: comparison of
patients before and after cardiac transplantation. Am J Med 1990;88:
493–6.
0. Hughes PD, Polkey MI, Harrus ML, Coats AJ, Moxham J, Green M.
Diaphragm strength in chronic heart failure. Am J Respir Crit Care
Med 1999;160:529–34.
1. Daganou M, Dimopoulou I, Alivizatos PA, Tzelepis GE. Pulmonary
function and respiratory muscle strength in chronic heart failure:
comparison between ischaemic and idiopathic dilated cardiomyopathy.
Heart 1999;81:618–20.
2. Lindsay DC, Lovegrove CA, Dunn MJ, et al. Histological abnormal-
ities of muscle from limb, thorax and diaphragm in chronic heart
failure. Eur Heart J 1996;17:1239–50.
3. Ohar J, Osterlah J, Ahmed N, Miller L. Diffusing capacity decreases
after heart transplantation. Chest 1993;103:857–61.
4. Standards for the diagnosis and care of patients with chronic obstruc-
tive pulmonary disease (COPD) and asthma. This official statement of
the American Thoracic Society was adopted by the ATS Board of
Directors, November 1986. Am Rev Respir Dis 1987;136:225–44.
5. Wagner PD, Dantzker DR, Dueck R, Clausen JL, West JB.
Ventilation-perfusion inequality in chronic obstructive pulmonary
disease. J Clin Invest 1977;59:203–16.
6. Wasserman K, Zhang YY, Gitt A, et al. Lung function and exercise
gas exchange in chronic heart failure. Circulation 1997;96:2221–7.
7. Kannel WB, Hubert H, Lew FA. Vital capacity as a predictor of
cardiovascular disease: the Framingham Study. Am Heart J 1983;105:
311–5.
8. Kannel WB, D’Agostino RB, Silbershatz H. Use of vital capacity for
cardiac failure risk estimation in persons with coronary disease and left
ventricular hypertrophy. Am J Cardiol 1996;77:1155–8.9. Weber KT, Kinasewitz GT, Janicki JS, Fishman AP. Oxygen utiliza-
tion and ventilation during exercise in patients with chronic cardiac
failure. Circulation 1982;65:1213–23.
0. Koike A, Michiaki H, Taniguchi T, Marumo F. Respiratory control
during exercise in patients with cardiovascular disease. Am Rev Respir
Dis 1993;147:425–9.
1. Myers J, Salleh MA, Buchanan N, et al. Ventilatory mechanism of
exercise intolerance in chronic heart failure. Am Heart J 1992;124:
710–9.
2. Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise venti-
lation in patients with chronic heart failure: intact ventilatory control
despite hemodynamic and pulmonary abnormalities. Circulation 1988;
77:552–9.
3. Henke KG, Sharratt M, Pegelow D, Dempsey JA. Regulation of
end expiratory lung volume during exercise. J Appl Physiol 1988;
64:135–46.
4. Spiro SG, Hahn HL, Edwards RH, Pride NB. An analysis of the
physiological strain of submaximal exercise in patients with chronic
obstructive bronchitis. Thorax 1975;30:415–25.
5. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of
-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985;
132:541–7.
6. Braat MC, Jonkers RE, van Boxtel CJ. Quantification of metoprolol
2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-
pharmacodynamic modeling. Pulm Pharmacol 1992;5:31–8.
7. Ellis ME, Sahay JN, Chatterjee SS, Cruickshank JM, Ellis SH.
Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Phar-
macol 1981;21:173–6.
8. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G.
Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol
on respiratory function in hypertensive patients with chronic obstruc-
tive lung disease. Cardiovasc Drugs Ther 1990;4:1145–9.
9. Fenster PE, Hasan FM, Abraham T, Woolfenden J. Effect of
metoprolol on cardiac and pulmonary function in chronic obstructive
pulmonary disease. Clin Cardiol 1983;6:125–9.
0. McGavin CR, Williams IP. The effects of oral propranolol and
metoprolol on lung function and exercise performance in chronic
airways obstruction. Br J Dis Chest 1978;72:327–32.
1. George RB, Manocha K, Burford JG, Conrad SA, Kinasewitz GT.
Effects of labetalol in hypertensive patients with chronic obstructive
pulmonary disease. Chest 1983;83:457–60.
2. Guazzi M, Agostoni P, Matturri M, Pontone G, Guazzi MD.
Pulmonary function, cardiac function, and exercise capacity in a
follow-up of patients with congestive heart failure treated with
carvedilol. Am Heart J 1999;138:460–7.
3. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerabil-
ity to carvedilol in patients with chronic heart failure. Heart
2000;84:615–9.
4. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ,
Glanville AR. Tolerability of carvedilol in patients with heart failure
and concomitant chronic obstructive pulmonary disease or asthma.
J Heart Lung Transplant 2002;21:1290–5.
5. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA
guidelines for the management of patients with acute myocardial
infarction. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee on
Management of Acute Myocardial Infarction). J Am Coll Cardiol
1999;34:890–911.
6. Macdonald P, Keogh A, Aboyoun C, Lund M, Amor R, McCaffrey
D. Tolerability and efficacy of carvedilol in patients with New York
Heart Association class IV heart failure. J Am Coll Cardiol 1999;33:
924–31.
7. Macdonald P, Keogh A, Aboyoun C, Lund M, Amor R, McCaffrey
D. Impact of concurrent amiodarone treatment on the tolerability and
efficacy of carvedilol in patients with chronic heart failure. Heart
1999;82:589–93.
8. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L.
Differential effects of beta-blockers in patients with heart failure. A
prospective, randomized, double-blind comparison of the long-term
effects of metoprolol vs. carvedilol. Circulation 2000;102:546–51.
9. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD,
Bristow MR. Carvedilol improves left ventricular function and symp-
toms in heart failure: a double-blind randomized study. J Am Coll
Cardiol 1995;25:1225–31.
55
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
6
502 Sirak et al. JACC Vol. 44, No. 3, 2004
Non-Selective Beta-Blockade in COPD and CHF August 4, 2004:497–5020. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind,
placebo-controlled study of the long-term efficacy of carvedilol in
patients with severe chronic heart failure. Circulation 1995;92:1499–
506.
1. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short-and
long-term carvedilol administration on rest and exercise hemody-
namic variables, exercise capacity and clinical conditions in patients
with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;
24:1678 –87.
2. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind,
placebo-controlled study of the effects of carvedilol in patients with
moderate to severe heart failure: the PRECISE trial. Circulation
1996;94:2793–9.
3. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces
dose-related improvements in left ventricular function and survival in
subjects with chronic heart failure. MOCHA Investigators. Circula-
tion 1996;94:2807–16.
4. Ind PW. Catecholamines. In: Barnes PJ, Grunstein MM, Leff AR,
Woolcock AJ, eds. Asthma. Philadelphia, PA: Lippincott-Raven,
1997:977–1008..
5. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyper-
reactivity. Am Rev Respir Dis 1980;121:389–413.
6. Barnes PJ. Neural control of human airways in health and disease. Am
Rev Respir Dis 1986;134:1289–314.
7. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway
obstruction due to emphysema. N Engl J Med 1984;311:421–5.
8. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic
and sympathomimetic treatment of asthma and chronic obstructive
airways disease in the emergency room. Am J Med 1987;82:59–64.
9. Roux E, Molimard M, Savineau JP, Marthan R. Muscarinic stimula-
tion of airway smooth muscle cells. Gen Pharmacol 1998;31:349–56.0. Sankary RM, Jones CA, Madison JM, Brown JK. Muscarinic cholin-
ergic inhibition of cyclic AMP accumulation in airway smooth muscle:
role of a pertussis toxin-sensitive protein. Am Rev Respir Dis
1988;138:145–50.
1. Yang CM, Chou SP, Sung TC. Muscarinic receptor subtypes coupled
to generation of different second messengers in isolated tracheal
smooth muscle cells. Br J Pharmacol 1991;104:613–8.
2. On LS, Boonyongsunchai P, Webb S, Davies L, Calverley PM,
Costello RW. Function of pulmonary neuronal M(2) muscarinic
receptors in stable chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2001;163:1320–5.
3. Godfrey S, Konig P. Inhibition of exercise-induced asthma by different
pharmacological pathways. Thorax 1976;31:137–43.
4. Ney UM. Propranolol-induced airway hyperreactivity in guinea-pigs.
Br J Pharmacol 1983;79:1003–10.
5. Van Mieghem W, Stevens E, Billiet L. Phentolamine therapy in
severe chronic asthmatiform bronchitis. Respiration 1981;42:
184 –7.
6. Black JL, Temple DM, Anderson SD. Long-term trial of an alpha-1
adrenoceptor blocking drug (Indoramin) in asthma: a preliminary
report. Scand J Respir Dis 1978;59:307–12.
7. Mathe AA, Astrom A, Persson NA. Some bronchoconstricting and
bronchodilating responses of human isolated bronchi: evidence for
the existence of alpha-adrenoceptors. J Pharm Pharmacol 1971;23:
905–10.
8. Malerba M, Agabiti-Rosei E. Respiratory effects of antihypertensive
agents acting on alpha adrenergic receptors. Recenti Prog Med
1991;82:682–5.
9. van Zwieten PA. Pharmacodynamic profile of carvedilol. Cardiology
1993;82 Suppl:19–23.
